SEC 13F Intelligence

Managers / Q1 2019 · view latest →

SV Health Investors, LLC

CIK 0001587143 · ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON, MA, 02108 · 617-367-8100

Reported Value
$170M
Q1 2019
Positions
8
Filings on Record
16
2019–present window
Filed
May 15, 2019
original filing

Summary

Sv Health Investors, LLC reported $170M in U.S.-listed holdings across 8 positions for Q1 2019.

The portfolio is heavily concentrated: Kalvista Pharmaceuticals alone accounts for 30.7% of reported value.

Compared with Q4 2018, the fund opened 2 new positions and exited 3.

Portfolio Metrics

Turnover
+5.2%
vs prior filed quarter
Largest Position
+30.7%
Kalvista Pharmaceuticals
New / Exited
2 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $162MQ4 ’18Q1 ’19: $170MQ2 ’19: $149MQ2 ’19Q3 ’19: $142MQ4 ’19: $165MQ4 ’19Q1 ’20: $119MQ2 ’20: $144MQ2 ’20Q3 ’20: $197MQ4 ’20: $208MQ4 ’20Q1 ’21: $267MQ2 ’21: $230MQ2 ’21Q3 ’21: $204MQ4 ’21: $155MQ4 ’21Q1 ’22: $83MQ2 ’22: $44MQ2 ’22Q3 ’22: $32Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 62.8%Other: 37.2%
  • Common Stock · 62.8% · $107M
  • Other · 37.2% · $63M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2018 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
X4 PharmaceuticalsNEW+311.5K311.5K+$5M$5M
CATABASIS PHARMACEUTICALS INNEW+285.8K285.8K+$2M$2M
ARSANIS INCSOLD OUT−1.87M0−$4M$0
CATABASIS PHARMACEUTICALS INSOLD OUT−285.8K0−$1M$0
RESHAPE LIFE SCIENCES INCSOLD OUT−1.1K0+$0$0
AVROBIO INCTRIMMED−805.3K1.93M−$3M$43M
KALVISTA PHARMACEUTICALS INCTRIMMED−716.7K1.83M+$2M$52M
DECIPHERA PHARMACEUTICALS INCHELD−49.0K1.24M+$2M$29M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2019

8 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1KALVISTA PHARMACEUTICALS INCCOM30.75%$52M1.83M
2AVROBIO INCCOM24.97%$43M1.93M
3DECIPHERA PHARMACEUTICALS INCCOM16.86%$29M1.24M
4SUTRO BIOPHARMA INCCOM12.19%$21M1.82M
5TRANSENTERIX INCCOM NEW9.26%$16M6.63M
6X4 PharmaceuticalsCOM3.18%$5M311.5K
7OCULOCULAR THERAPEUTIX INChistory →COM1.46%$2M628.2K
8CATABASIS PHARMACEUTICALS INCOM NEW1.33%$2M285.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$32M4Nov 7, 202213F-HRchanges · EDGAR ↗
Q2 2022$44M5Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$83M5May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M6Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$204M8Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$230M7Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$267M8May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$208M9Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$197M10Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$144M10Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$119M10May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$165M10Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$142M10Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$149M9Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$170M8May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$162M9Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 4 additional managers.

  • SVLSF IV, LLC028-16272
  • SV Life Sciences Fund IV (GP), L.P.028-16273
  • SVLSF VI, LLC028-19256
  • SV Life Sciences Fund VI (GP), L.P.028-19255

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.